The Lancet published the Phase III clinical trial results on the safety and efficacy of “Ad5-nCoV”
Dec 23, 2021，CanSino Biologics Inc. announced that The Lancet published its Phase III clinical trial results on the safety and efficacy of its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Ad5-nCoV”, trade name: Convidecia™). The publication of the analysis showed that a single dose of Convidecia™ is efficacious and safe with an efficacy of 96.0% in preventing …